Skip to content
Screener

Vertex Pharmaceuticals VRTX Business Segments — Provision for income taxes

Similar metrics at other companies

FinWise Bancorp logo
FINWBaaS — Provision for income taxes
$1.19M
Target logo
TGTReportable Segment — Provision for income taxes
$252M-27.2%
Adobe logo
ADBEReportable Segment — Provision for income taxes
$526M+28.3%
Samsara logo
IOTReportable Segment — Provision for income taxes
$4.42M+178%
Zoom Video Communications, Inc. logo
ZMReportable Segment — Provision for income taxes
$105.94M+73.2%
AWK
AWKRegulated Businesses — Provision for income taxes
$61M+1.7%

Other financials

Income statement

See full
Revenue$3.3B+12.5%
Gross profit$2.8B+11.2%
Operating income$1.2B+8.3%
Net income$1.1B+6.5%
EPS (diluted)$4.31+8.0%

Balance sheet

See full
Cash & equivalents$7.9B+57.6%
Total debt$2.0B+29.5%
Total equity$20.2B+17.9%
Total assets$27.4B+14.1%

Cash flow

See full
Operating cash flow$1.4B+74.4%
CapEx$133.4M+228%
Free cash flow$1.3B+66.4%

Valuation

See full
Market cap$122.68B+24.1%
Enterprise value$116.81B+22.4%
P/E27.9×
P/S9.8×+1.1×

Profitability

See full
Gross margin86%-0.1pp
Operating margin38%
Net margin35%
FCF margin30.4%+20.2pp

Returns & leverage

See full
Return on equity23.5%
Debt / equity0.1×0.0×
Current ratio3.2×+0.7×

Where this comes from

Reported directly by Vertex Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000875320-26-000173
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Acquired in-process research and development expenses0.519.8
Selling and other commercial expenses313.6241.1
General and administrative expenses180.1155.3
Intangible asset impairment charge379.0
Interest income, net(114.8)(117.9)
Other segment items (1)0.219.8
Provision for income taxes221.584.1
Net income$1,031.4$646.3

Item 1. Financial Statements (unaudited)

FAQ

What is Vertex Pharmaceuticals's business segments — provision for income taxes?
Vertex Pharmaceuticals (VRTX) reported business segments — provision for income taxes of $221.5M in Q1 2026.
How has Vertex Pharmaceuticals's business segments — provision for income taxes changed year-over-year?
Vertex Pharmaceuticals's business segments — provision for income taxes increased by 163.4% year-over-year, from $84.1M to $221.5M.
What is the long-term trend for Vertex Pharmaceuticals's business segments — provision for income taxes?
Over 3 years (2022 to 2025), Vertex Pharmaceuticals's business segments — provision for income taxes has grown at a -8.8% compound annual growth rate (CAGR), from $910.4M to $690M.
What does business segments — provision for income taxes mean?
The estimated tax expense calculated on the company's pre-tax earnings based on applicable tax jurisdictions. This reflects the company's effective tax burden.

Ask your AI about Vertex Pharmaceuticals's business segments — provision for income taxes.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude